Keystone Bio
About Keystone Bio
Keystone Bio is a biotech company focused on targeting a unique inflammapath using advanced PharmaBiome technology. This approach aims to address inflammatory diseases by developing precise therapeutic interventions that improve patient outcomes.
<problem> Many inflammatory diseases lack targeted therapies, leading to broad immunosuppression and suboptimal patient outcomes. Current treatments often fail to address the root causes of inflammation, resulting in chronic conditions and significant side effects. </problem> <solution> Keystone Bio is developing targeted therapeutics using its PharmaBiome technology to address the underlying inflammapathways driving inflammatory diseases. This approach aims to precisely modulate the microbiome to reduce inflammation and improve patient outcomes. By focusing on the interaction between the microbiome and the immune system, Keystone Bio seeks to develop more effective and safer treatments for a range of inflammatory conditions. </solution> <features> - PharmaBiome technology platform for targeted modulation of the microbiome - Focus on inflammapathways to address root causes of inflammatory diseases - Development of precise therapeutic interventions </features> <target_audience> Keystone Bio's primary customers are patients suffering from inflammatory diseases and the healthcare providers who treat them. </target_audience>
What does Keystone Bio do?
Keystone Bio is a biotech company focused on targeting a unique inflammapath using advanced PharmaBiome technology. This approach aims to address inflammatory diseases by developing precise therapeutic interventions that improve patient outcomes.
When was Keystone Bio founded?
Keystone Bio was founded in 2018.
How much funding has Keystone Bio raised?
Keystone Bio has raised 5000000.
- Founded
- 2018
- Funding
- 5000000
- Employees
- 4 employees